Skip to content

Insider · CIK 0001865490

Kristin Stephens

officer

Files at SYRS (Syros Pharmaceuticals, Inc.). First filing Nov 20, 2024, latest Nov 20, 2024.

In brief

Kristin Stephens files SEC Form 4 as officer at SYRS (Syros Pharmaceuticals, Inc.). Since Nov 20, 2024, Kristin Stephens has reported 0 open-market buys worth $0 and 1 open-market sell worth $7,949, the latest filed on Nov 20, 2024.

A track record needs three past buys with six months of prices behind them; Kristin Stephens has 0, so none is measured yet.

The newest scored trade: sold $7,949 of SYRS on Nov 18, 2024, filed Nov 20, 2024, scored 50 (moderate).

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $7,949 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

SYRS: Syros Pharmaceuticals, Inc.

SYRSOct 9, 2026 · close 0.00

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
50Moderate
SYRSsell 6
Syros Pharmaceuticals, Inc.
$7,949
36,133 shares
-100%-

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Nov 18, 2024 SYRS
Syros Pharmaceuticals, Inc.
36,133
0.13% of outstanding
$7,949Nov 18, 2024$13k

Transactions

Every row this insider has filed, 4 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Nov 18, 2024SYRS
Syros Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-36,133$0.22$7,9490Nov 20, 2024
Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
MOption exercise
Common Stock10b5-1
+17,000--42,237Nov 4, 2024
Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
FTax withholding
Common Stock10b5-1
-6,104$2.09$13k36,133Nov 4, 2024
Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-17,000$0.00$00Nov 4, 2024

Questions about Kristin Stephens

Answered from the filings on this page, as of the latest one.

Is Kristin Stephens buying or selling?

Not in the last 12 months. Kristin Stephens's latest open-market trade on SEC Form 4 was sold $7,949 of SYRS on Nov 18, 2024.

How did Kristin Stephens's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kristin Stephens has 0.

Where does Kristin Stephens file Form 4?

Kristin Stephens has filed Form 4 at SYRS (Syros Pharmaceuticals, Inc.) as Chief Development Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kristin Stephens: insider trades and track record | InsiderTell